Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EPS (Weighted Average and Diluted) (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.43 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 147.78% to $0.43 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.42 through Dec 2025, up 18.79% year-over-year, with the annual reading at -$2.42 for FY2025, 18.79% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.43 at 4D Molecular Therapeutics, up from -$1.01 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.43 in Q4 2025, with the low at -$1.01 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.7, with a median of -$0.82 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 229.17% in 2024, then soared 147.78% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.85 in 2021, then increased by 1.18% to -$0.84 in 2022, then grew by 8.33% to -$0.77 in 2023, then decreased by 16.88% to -$0.9 in 2024, then soared by 147.78% to $0.43 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $0.43, -$1.01, and -$0.98 for Q4 2025, Q3 2025, and Q2 2025 respectively.